Standard BioTools Inc (NASDAQ: LAB) kicked off on Tuesday, up 6.72% from the previous trading day, before settling in for the closing price of $1.19. Over the past 52 weeks, LAB has traded in a range of $0.97-$2.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 11.99%. While this was happening, its average annual earnings per share was recorded 65.38%. With a float of $364.90 million, this company’s outstanding shares have now reached $377.53 million.
The extent of productivity of a business whose workforce counts for 818 workers is very important to gauge. In terms of profitability, gross margin is 48.31%, operating margin of -100.46%, and the pretax margin is -79.29%.
Standard BioTools Inc (LAB) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Standard BioTools Inc is 3.72%, while institutional ownership is 73.81%. The most recent insider transaction that took place on Feb 28 ’25, was worth 5,134,321. In this transaction Director of this company bought 4,820,959 shares at a rate of $1.06, taking the stock ownership to the 58,846,780 shares. Before that another transaction happened on Nov 12 ’24, when Company’s Former Officer proposed sale 57,971 for $2.12, making the entire transaction worth $123,098.
Standard BioTools Inc (LAB) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 65.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 57.47% during the next five years compared to 11.61% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Take a look at Standard BioTools Inc’s (LAB) current performance indicators. Last quarter, stock had a quick ratio of 5.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.55, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.09 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
The latest stats from [Standard BioTools Inc, LAB] show that its last 5-days average volume of 0.88 million was inferior to 1.82 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 92.40%. Additionally, its Average True Range was 0.09.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 23.37%, which indicates a significant decrease from 100.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.82% in the past 14 days, which was higher than the 87.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1786, while its 200-day Moving Average is $1.7020. Now, the first resistance to watch is $1.2900. This is followed by the second major resistance level at $1.3100. The third major resistance level sits at $1.3500. If the price goes on to break the first support level at $1.2300, it is likely to go to the next support level at $1.1900. The third support level lies at $1.1700 if the price breaches the second support level.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
The company with the Market Capitalisation of 481.31 million has total of 378,986K Shares Outstanding. Its annual sales at the moment are 174,430 K in contrast with the sum of -138,890 K annual income. Company’s last quarter sales were recorded 46,720 K and last quarter income was -34,070 K.
